BMS lowers IPO target to $600M

In what analysts see as a test of the paltry IPO market, Bristol-Myers Squibb will sell off part of its Mead Johnson subsidiary for $21 to $24 per share, hoping to bring in $600 million. That's a lot less than it originally expected to raise from Mead Johnson: $1 billion. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.